Companies · Biotechnology

Biowish Technologies International Inc.

CINCINNATI · Biotechnology

Diligence memoA one-page analyst read on Biowish Technologies International Inc. — recommendation, valuation, rhythm, risks.
$34.4M
Total raised · real
7
Rounds
0.4×
Latest step-up
Top 25%
Sector rank · raised
Series A
Latest stage · inferred · Thu Aug 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Biowish Technologies International Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.35× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Biowish Technologies International Inc. is one of 4291 Biotechnology companies tracked from CINCINNATI. By capital raised it ranks in the upper tier (ahead of 76% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
10
Investors (latest)
2023-08-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2013-06-27 Raised $12M (real) Modeled valuation $424M (est)Series A2013Series A · 2015-08-14 Raised $3.0M (real) Modeled valuation $108M (est)Series A2015Series A · 2017-02-17 Raised $3.1M (real) Modeled valuation $112M (est)Series A2017Series A · 2017-08-31 Raised $2.1M (real) Modeled valuation $76M (est)Series A2017Series A · 2018-08-31 Raised $7.5M (real) Modeled valuation $269M (est)Series A2018Series A · 2022-07-29 Raised $5.0M (real) Modeled valuation $66M (est)Series A2022Series A · 2023-08-17 Raised $2.0M (real) Modeled valuation $16M (est)Series A2023+$3.0M+$3.1M+$2.1M+$7.5M+$5.0M+$2.0MCumulative $34M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.7M · 2013
Series A extension$3.0M · 2015
Series A extension$3.1M · 2017
Series A extension$2.1M · 2017
Series A extension$7.5M · 2018
Series A extension$5.0M · 2022
Series A extension$2.0M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$15.7M
Base estimate est.
$2.1M
Conservative case
$41.5M
Upside case
$8.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $424.4M · 2013-06-272013Series A · modeled $108.5M · 2015-08-14Series A · modeled $112.1M · 2017-02-17Series A · modeled $76.3M · 2017-08-31Series A · modeled $269.5M · 2018-08-31Series A · modeled $66.4M · 2022-07-29Series A · modeled $15.7M · 2023-08-172023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.9 yr
Elapsed time used
2.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$3.4M/yr
Capital velocity
13.0 yr
On record since
2013
First round
7
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.8× above median
This company$34.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$15.7M
Sector median$64.2M

Raised more than 76% of sector peers (real $). Modeled value above 25% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #252 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Biowish Technologies International Inc. (this company) Raised $34.4M · modeled $15.7M (est)Biowish Technologies International Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Biowish Technologies International Inc. this companySeries A$34.4M$15.7M0.35×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.7M2013-06-27$53.4M$424.4M85%
Series A$3.0M2015-08-14$13.6M$108.5M85%
Series A$3.1M2017-02-17$14.1M$112.1M90%
Series A$2.1M2017-08-31$9.6M$76.3M90%
Series A$7.5M2018-08-31$33.9M$269.5M90%
Series A$5.0M2022-07-29$22.7M$66.4M90%
Series A$2.0M2023-08-17$8.9M$15.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.7M2013-06-27
    • First recorded raise — entered as Series A.
    • 21 investors on this round.
  2. Series A$3.0M2015-08-14
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 3.9× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  3. Series A$3.1M2017-02-17
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 27 investors on this round.
  4. Series A$2.1M2017-08-31
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 26 investors on this round.
  5. Series A$7.5M2018-08-31
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 31 investors on this round.
  6. Series A$5.0M2022-07-29
    • Raised again after 47 mo — slower than the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  7. Series A$2.0M2023-08-17
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 10 investors on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~20mo cadence
$2.0M
Modeled next size est.range $2.0M$3.1M
0.4×
Last step-up
$3.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Douglas Cameron4 other2023-08
Jeffrey S. McCormick3 other2023-08
A. Charles Funai2015-08
David M Eller2015-08
Diane Charles Perry2017-08
Geoff M Rosenhain2015-08
Geoff S. Rosenhain2013-06
Ian Edwards2013-06
Irwin Heller2013-06
Irwin M Heller2015-08
Jeffrey M McCormick2015-08
Jeffrey S. McCormack2013-06
John M Zuske2015-08
John Zuske2013-06
Nabil M Sakkab2015-08
Nabil Sakkab2023-08
Nabil S. Sakkab2013-06
Rod Charles Vautier2017-08
Rodney S. Vautier2023-08
Stephen S. Kent2023-08
Registry & provenance

Biowish Technologies International Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1581101
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Elixirgen Therapeutics, Inc.BiotechnologySeries A$34.1M$11.0Msame sector · same stage
Orgenesis Inc.BiotechnologySeries A$35.2M$14.4Msame sector · same stage
Alume Biosciences IncBiotechnologySeries A$33.4M$18.9Msame sector · same stage
Trefoil Therapeutics, Inc.BiotechnologySeries A$33.3M$16.2Msame sector · same stage
Imunon, Inc.BiotechnologySeries A$35.5M$11.0Msame sector · same stage
CHF Solutions, Inc.BiotechnologySeries A$33.0M$17.0Msame sector · same stage
Acurx Pharmaceuticals, LLCBiotechnologySeries A$30.1M$13.1Msame sector · same stage
Prelude CorpBiotechnologySeries A$40.9M$13.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Photoswitch Biosciences, Inc.BiotechnologyPre-Seed$27.6M89%
Bio2 Technologies, Inc.BiotechnologySeries A$16.4M88%
Biotheryx, Inc.BiotechnologySeries C$2.7B88%
Cascade Biocatalysts, Inc.BiotechnologySeries A$16.8M88%
BioPhoundry, Inc.BiotechnologySeed$4.3M87%
MetaBiotech CorpBiotechnologySeries A$331.8M87%
BioNADrx Holdings, Inc.BiotechnologyPre-Seed$747K87%
SwitchPoint Bio Holding, Inc.BiotechnologySeries A$12.3M87%
Frequently asked
How much funding has Biowish Technologies International Inc. raised?
Biowish Technologies International Inc. has raised approximately $34.4M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is Biowish Technologies International Inc.'s estimated valuation?
Provath's modeled valuation for Biowish Technologies International Inc. is approximately $15.7M (modeled range $2.1M–$41.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Biowish Technologies International Inc. at?
Biowish Technologies International Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Aug 17.
What does Biowish Technologies International Inc. do and where is it based?
Biowish Technologies International Inc. operates in the Biotechnology sector, based in CINCINNATI.
Explore related

See where Biowish Technologies International Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Biowish Technologies International Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.